Par Pharma nabs injectables specialist JHP for $490M in private-equity auction

Tracy Staton Generics maker Par Pharmaceutical inked a deal to pay $ 490 million for JHP Pharmaceuticals, a specialty pharma company owned by Warburg Pincus. Par will gain a portfolio ...

Sanofi launches a new antibiotics effort, teams with Fraunhofer

John Carroll Sanofi is joining forces with researchers at Germany's Fraunhofer-Gesellschaft in the hunt for new antibiotics. The pharma giant is setting up a new collaboration that ...

Google Ventures backs DNAnexus’ $15M round for R&D cloud platform

John Carroll Google Ventures has joined a group of investors seeding DNAnexus' cloud-computing services for biomedical researchers with a $ 15 million C round. FierceBiotech News

FDA smacks Hospira with nearly 2 dozen observations at India plant

Eric Palmer Hospira is getting on top of its manufacturing issues in the U.S. But the company continues to face issues at a plant in India that received a warning letter in ...

Doxil update: J&J strikes deal to manufacture Doxil itself at Ben Venue plant

Eric Palmer Janssen Pharmaceuticals, which has struggled to maintain supplies of its cancer drug Doxil since supplier Ben Venue Laboratories ran into FDA issues, may have landed on ...

Branded or Generic? Adults Share Preferences in Study

mia.burns By Mia Burns (mia.burns@ubm.com) Close to 16 percent, or 37 million of adults agree that paying more for branded prescription medications rather than getting generic products, ...

New reports put India’s Torrent at forefront of buyers for Elder Pharmaceuticals

Eric Palmer The Economic Times now says Elder is deep into discussions with Indian drugmaker Torrent Pharma, which is talking about 1,700 crore ($ 291 million) for its peer. FiercePharma ...

Relax, PCSK9ers: FDA won’t roadblock blockbusters from Sanofi, Amgen

Damian Garde On the heels of new guidelines casting doubts on a much-hyped new class of cholesterol drugs, the FDA said it would not demand long and costly outcomes trials before approving ...

Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly

barbara.lempert Zysis Receives US Patent for Long Acting Oral Aripiprazole Once Weekly First-in-class antipsychotic therapy for Schizophrenia and Bipolar Disorders London, UK, 13 ...

Sanofi gets mixed FDA blessing for MS drug Lemtrada

Damian Garde After a scathing staff review, Sanofi walked away from an FDA panel with mixed messages on its long-delayed multiple sclerosis drug, as agency advisers said the injection ...

After Bristol-Myers R&D cuts, will AstraZeneca amp up its share of diabetes JV?

Tracy Staton When Bristol-Myers Squibb reported earnings last week, it seemed fully committed to AstraZeneca and their multibillion-dollar diabetes joint venture. Sales growth there ...

Ariad hacks 160 workers in aftermath of Iclusig disaster

Tracy Staton Ariad Pharmaceuticals is letting go of nearly half its U.S. staff just a week after pulling its leukemia drug Iclusig from the market at the FDA's request. FiercePharma ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS